Clarithromycin

• CAT Number: A000923
• CAS Number: 81103-11-9
• Molecular Formula: C38H69NO13
• Molecular Weight: 748.00
• Purity: 98%
• Synonyms: 81103-11-9; Biaxin; 6-O-Methylerythromycin; Clarithromycine; Clathromycin
• Target: Metabolic Enzyme/Protease
• Target Protein: P51164
• Solubility: >31.2mg/mL in DMSO
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
• InChI: InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
• InChIKey: AGOYDEPGAOXOCK-KCBOHYOISA-N
• SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O

Clarithromycin（Cat No.:A000923）is a macrolide antibiotic used to treat various bacterial infections, including respiratory tract infections, skin infections, and Helicobacter pylori-associated ulcers. It works by inhibiting bacterial protein synthesis, preventing the growth and spread of bacteria. Clarithromycin is effective against a wide range of gram-positive and gram-negative bacteria. Its ability to penetrate tissues and cells makes it particularly useful for treating intracellular infections. With a favorable safety profile, clarithromycin is often prescribed for conditions like pneumonia, bronchitis, and sinusitis, improving patient outcomes in both acute and chronic infections.

Reference

1: Carvalho NFG, Pavan F, Sato DN, Leite CQF, Arbeit RD, Chimara E. Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41). J Antimicrob Chemother. 2017 Dec 18. doi: 10.1093/jac/dkx476. [Epub ahead of print] PubMed PMID: 29272470.
2: Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2017 Dec 21. doi: 10.1111/hel.12456. [Epub ahead of print] PubMed PMID: 29271026.
3: Adachi T, Matsui S, Watanabe T, Okamoto K, Okamoto A, Kono M, Yamada M, Nagai T, Komeda Y, Minaga K, Kamata K, Yamao K, Takenaka M, Asakuma Y, Sakurai T, Nishida N, Kashida H, Kudo M. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. Oncology. 2017;93 Suppl 1:15-19. doi: 10.1159/000481224. Epub 2017 Dec 20. PubMed PMID: 29258111.
4: Deng J, Chen F, Lai Y, Luo Q, Xu R, Ou C, Fu Q, Shi J. Lack of additional effects of long-term, low-dose clarithromycin combined treatment compared with topical steroids alone for chronic rhinosinusitis in China: a randomized, controlled trial. Int Forum Allergy Rhinol. 2017 Nov 30. doi: 10.1002/alr.22041. [Epub ahead of print] PubMed PMID: 29195025.
5: Sue S, Suzuki N, Shibata W, Sasaki T, Yamada H, Kaneko H, Tamura T, Ishii T, Kondo M, Maeda S. First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin. Gastroenterol Res Pract. 2017;2017:2019802. doi: 10.1155/2017/2019802. Epub 2017 Oct 18. PubMed PMID: 29181022; PubMed Central PMCID: PMC5664290.
6: Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter. 2017 Nov 26. doi: 10.1111/hel.12452. [Epub ahead of print] PubMed PMID: 29178562.
7: Inghammar M, Nibell O, Pasternak B, Melbye M, Svanström H, Hviid A. Long Term Risk of Cardiovascular Death With Use of Clarithromycin and Roxithromycin – a Nationwide Cohort Study. Am J Epidemiol. 2017 Nov 16. doi: 10.1093/aje/kwx359. [Epub ahead of print] PubMed PMID: 29155931.
8: Yatera K, Umeki K, Yamasaki K, Noguchi S, Nishida C, Ishimoto H, Sakamoto N, Ishii H, Kadota JI, Mukae H. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. Respir Investig. 2017 Nov;55(6):380-383. doi: 10.1016/j.resinv.2017.07.005. Epub 2017 Sep 23. PubMed PMID: 29153420.
9: Moon SH, Zhang X, Zheng G, Meeker DG, Smeltzer MS, Huang E. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. J Med Chem. 2017 Dec 14;60(23):9630-9640. doi: 10.1021/acs.jmedchem.7b01064. Epub 2017 Nov 22. PubMed PMID: 29136469.
10: Redondo JJ, Keller PM, Zbinden R, Wagner K. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. Diagn Microbiol Infect Dis. 2018 Jan;90(1):1-6. doi: 10.1016/j.diagmicrobio.2017.09.014. Epub 2017 Sep 25. PubMed PMID: 29111147.